Insights

Market leadership Alkermes operates in neuroscience focused biopharma with a broad portfolio of marketed medicines and an investigational pipeline, presenting multiple cross-sell and upsell opportunities across psychiatry, neurology, addiction, sleep disorders, and related care settings.

Strategic expansions Recent press indicates active data presentations and ongoing sleep medicine initiatives, suggesting potential partnerships or co-development opportunities around LUMRYZ and related sleep disorder therapies, as well as possible expansion of commercial footprints in Europe and the US.

Clinical and payer readiness Alkermes emphasizes patient-inspired science and integrated development with specialized commercial infrastructure, implying readiness to engage payer strategies, real-world evidence generation, and value-based pricing discussions to support market access.

Financial positioning With revenue in the single to multi-billion range and ongoing quarterly financial disclosures, there is room to discuss capacity for additional manufacturing partnerships, co-promotion agreements, or supply agreements aligned with demand from CNS indications and sleep disorders.

Key stakeholder access Headquartered in Ireland with a US R&D center and Ohio manufacturing site, Alkermes offers regional collaboration opportunities, channel strategy flexibility, and access to its international clinical expertise for region-specific market development.

Similar companies to Alkermes

Alkermes Tech Stack

Alkermes uses 8 technology products and services including Microsoft Clarity, AutoCAD, Adobe Experience Manager, and more. Explore Alkermes's tech stack below.

Media & News

Alkermes's Email Address Formats

Alkermes uses at least 4 email formats:
Alkermes Email FormatsExamplePercentage
First.Last@alkermes.comJohn.Doe@alkermes.com
94%
FLast@alkermes.comJDoe@alkermes.com
4%
Last_First@alkermes.comDoe_John@alkermes.com
1%
First.Middle@alkermes.comJohn.Michael@alkermes.com
1%

Frequently Asked Questions

What is Alkermes's phone number?

Minus sign iconPlus sign icon
You can contact Alkermes's main corporate office by phone at . For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is Alkermes's stock symbol?

Minus sign iconPlus sign icon
Alkermes is a publicly traded company; the company's stock symbol is ALKS.

What is Alkermes's official website and social media links?

Minus sign iconPlus sign icon
Alkermes's official website is alkermes.com and has social profiles on LinkedIn and Crunchbase.

How much revenue does Alkermes generate?

Minus sign iconPlus sign icon
As of October 2026, Alkermes's annual revenue is estimated to be $1B - $10B.

What is Alkermes's SIC code and NAICS code?

Minus sign iconPlus sign icon
Alkermes's SIC code is 8731 - Commercial Physical and Biological Research and NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Alkermes have currently?

Minus sign iconPlus sign icon
As of October 2026, Alkermes has approximately 2.4K employees across 5 continents, including North America, Europe and Asia. Key team members include Chief Legal Officer, Senior Vice President: E. S., Chief Financial Officer: R. L. and Vice President Of Quality, Development & External: C. D. Explore Alkermes's employee directory with LeadIQ.

What industry does Alkermes belong to?

Minus sign iconPlus sign icon
Alkermes operates in the Biotechnology Research industry.

What technology does Alkermes use?

Minus sign iconPlus sign icon
Alkermes's tech stack includes Microsoft Clarity, AutoCAD, Adobe Experience Manager, Salesforce, Pardot, Screaming Frog SEO Spider, Citrix and Webex.

What is Alkermes's email format?

Minus sign iconPlus sign icon
Alkermes's email format typically follows the pattern of First.Last@alkermes.com. Find more Alkermes email formats with LeadIQ.

How much funding has Alkermes raised to date?

Minus sign iconPlus sign icon
As of October 2026, Alkermes has raised $250M in funding. The last funding round occurred on Nov 20, 2017.

When was Alkermes founded?

Minus sign iconPlus sign icon
Alkermes was founded in 1987.
Alkermes logo

Alkermes

Biotechnology ResearchDublin, Ireland1001-5000 Employees

Alkermes is a biotechnology company focused on neuroscience, developing medicines for complex psychiatric and neurological disorders, including addiction, serious mental illness, and sleep disorders. It combines patient-informed science with an integrated research strategy and development and commercial capabilities to advance therapies for chronic conditions that have historically been overlooked or stigmatized. The organization emphasizes its people and empathy for patients, families, and caregivers as a central strength shaping its culture. The company is headquartered in Dublin, Ireland, with a corporate office and research and development center in Massachusetts and a manufacturing facility in Ohio.

In June 2026, Alkermes announced positive results from the Vibrance-2 Phase 2 study of alixorexton in adults with narcolepsy type 2, reporting improvements on wakefulness and sleepiness measures. The company also announced orphan drug designations from the U.S. FDA and European authorities for alixorexton in the treatment of idiopathic hypersomnia and narcolepsy, reflecting regulatory recognition for its sleep-disorder program.

Section iconCompany Overview

Phone number
SIC Code
8731 - Commercial Physical and Biological Research
Stock Symbol
ALKS
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
1987
Employees
1001-5000

Section iconFunding & Financials

  • $250M

    Alkermes has raised a total of $250M of funding over 2 rounds. Their latest funding round was raised on Nov 20, 2017 as a Post IPO Equity.

  • $1B - $10B

    Alkermes's revenue is estimated to be in the range of $1B - $10B

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.